0001592342-18-000002.txt : 20180105 0001592342-18-000002.hdr.sgml : 20180105 20180105121110 ACCESSION NUMBER: 0001592342-18-000002 CONFORMED SUBMISSION TYPE: D/A PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20180105 DATE AS OF CHANGE: 20180105 EFFECTIVENESS DATE: 20180105 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vitruvias Therapeutics, Inc. CENTRAL INDEX KEY: 0001592342 IRS NUMBER: 463308985 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D/A SEC ACT: 1933 Act SEC FILE NUMBER: 021-301275 FILM NUMBER: 18512675 BUSINESS ADDRESS: STREET 1: 670 NORTH COLLEGE STREET STREET 2: SUITE B CITY: AUBURN STATE: AL ZIP: 36830 BUSINESS PHONE: 334-329-5601 MAIL ADDRESS: STREET 1: 670 NORTH COLLEGE STREET STREET 2: SUITE B CITY: AUBURN STATE: AL ZIP: 36830 FORMER COMPANY: FORMER CONFORMED NAME: Vitruvias Therapeutics, LLC DATE OF NAME CHANGE: 20131119 D/A 1 primary_doc.xml X0708 D/A LIVE 0001592342 Vitruvias Therapeutics, Inc. 670 NORTH COLLEGE STREET SUITE B AUBURN AL ALABAMA 36830 334-329-5601 DELAWARE Vitruvias Therapeutics, LLC Corporation true 2013 Carl L Whatley 670 North College Street Suite B Auburn AL ALABAMA 36830 Executive Officer Director Bryce M Harvey 110 Courtyard Circle Santa Rosa Beach FL FLORIDA 32429 Executive Officer Director Roger D Graben 670 North College Street Suite B Auburn AL ALABAMA 36830 Executive Officer Jason Wild 489 Fifth Avenue, 29th Floor New York NY NEW YORK 10017 Director Upon consummation of stock purchase transaction, he became a director. Michael Altman 51 Astor Place, 10th floor New York NY NEW YORK 10003 Director Upon consummation of stock purchase transaction, he became a director. Edward Schutter 1803 Newstead Trace Marietta GA GEORGIA 30062 Director Upon consummation of stock purchase transaction, he became a director. Pharmaceuticals No Revenues 06b true 0001592342-17-000003 2017-12-26 false true false 25000 11500000 11500000 0 Sale occurred on December 26, 2017. false 23 0 0 1510000 true Bryce Harvey owns the majority of interests in H2-Pharma,LLC, which loaned money to the issuer. $1,500,000 will be used to pay down principal of that loan. $10,000 will be used to pay H2 Pharma, officers & directors interest on loans made to Company. false Vitruvias Therapeutics, Inc. Carl L. Whatley, Jr. Carl L. Whatley, Jr. President 2018-01-05